It was also reported that mice with ARID1A mutations were more sensitive to PD-L1 immune checkpoint blockade in ovarian and colorectal cancer models than wild-type mice, indicating that ARID1A deficiency could be coordinated with immune checkpoint blockade therapy (Shen et al., 2018). This evidence concerns the gene ARID1A and colorectal cancer.